Search for: "Pfizer, Inc." Results 901 - 920 of 1,512
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
18 Apr 2008, 4:51 pm
Metro Area Medical Malpractice Law Blog Alaska, a leader in pet trusts - Florida attorney Danny Meek in his Pet Trust Law Blog Mississippi Supreme Court asked to interpret anti-concurrent cause in interlocutory appeal - Portland lawyer David Rossmiller of Dunn Carney in the firm's Insurance Coverage Law Blog Pfizer proves that biggest is not always best - Management consultant Cliff Mintz of BioInsights Inc. in his Bio Job Blog [read post]
12 Jan 2012, 4:30 am by Ray Mullman
 Another sponsor was pharmaceutical giant Pfizer Inc, which has an enormous financial stake in the outcome of the litigation. [read post]
23 May 2008, 5:38 am
" Chantix, made by Pfizer, Inc., was attacked in a study by a non-profit group on Wednesday for possible links to seizures, dizziness, heart irregularity, diabetes and more than 100 accidents. [read post]
19 Sep 2013, 9:53 am by Bexis
Pfizer, Inc., 712 F.3d 21 (1st Cir. 2013), Aetna, Inc. v. [read post]
11 Sep 2015, 4:00 am by Alan Macek
Apotex, Inc., [1990] 1 F.C. 221 (F.C.A.), the Court held that evidence on irreparable harm must be “clear and not speculative”. [read post]
11 Jun 2007, 8:03 am
The Court refused to expedite consideration of a new patent appeal by Pfizer Inc., a case in which Justice John Paul Stevens refused last week to provide temporary relief. [read post]
5 Oct 2016, 11:44 am by John Suthers
  In another similar case involving a drug manufacturer, a former sales representative of Pfizer, Inc., brought a qui tam lawsuit, alleging the manufacturer engaged in off-label marketing of its painkiller, Bextra. [read post]
5 Oct 2016, 11:44 am by John Suthers
  In another similar case involving a drug manufacturer, a former sales representative of Pfizer, Inc., brought a qui tam lawsuit, alleging the manufacturer engaged in off-label marketing of its painkiller, Bextra. [read post]
24 May 2021, 7:34 am by Deb Givens
The plaintiffs have accused Ranbaxy of delaying the launch of generic versions of Novartis AG’s high blood pressure drug Diovan, Pfizer Inc’s acid reflux drug Nexium and Genentech Inc’s antiviral drug Valcyte. [read post]